Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options. Genomic amplification and/or overexpression of the MYC oncogene is a common molecular event in HCC, thus making it an attractive target for drug therapy. Unfortunately, currently there are no direct...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Dhanasekaran, Renumathy, Gabay-Ryan, Meital, Baylot, Virginie, Lai, Ian, Mosley, Adriane, Huang, Xinqiang, Zabludoff, Sonya, Li, Jian, Kaimal, Vivek, Karmali, Priya, Felsher, Dean W.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814155/
https://ncbi.nlm.nih.gov/pubmed/29464015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22342
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados